慢性阻塞性肺疾病的急性加重：它们会导致疾病进展吗？
Exacerbations in chronic obstructive pulmonary disease: do they contribute to disease progression?
作者信息
Silverman Edwin K
机构信息
Channing Laboratory and Pulmonary and Critical Care Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
出版信息
Proc Am Thorac Soc. 2007 Dec;4(8):586-90. doi: 10.1513/pats.200706-068TH.
Abstract
The impact of chronic obstructive pulmonary disease (COPD) exacerbations on decline in FEV(1) has been a controversial topic for decades. We will review some of the key studies in this area and discuss potential contributors to inconsistent results of these studies. Dissecting the heterogeneous COPD syndrome into meaningful subtypes and assessing the genetic and environmental influences on COPD-related phenotypes such as exacerbation frequency could clarify the impact of exacerbations on the natural history of COPD.
摘要
数十年来，慢性阻塞性肺疾病（COPD）急性加重对第一秒用力呼气容积（FEV₁）下降的影响一直是一个有争议的话题。我们将回顾该领域的一些关键研究，并讨论这些研究结果不一致的潜在原因。将异质性的COPD综合征分解为有意义的亚型，并评估遗传和环境对COPD相关表型（如急性加重频率）的影响，可能会阐明急性加重对COPD自然病程的影响。
相似文献
1
Exacerbations in chronic obstructive pulmonary disease: do they contribute to disease progression?
Proc Am Thorac Soc. 2007 Dec;4(8):586-90. doi: 10.1513/pats.200706-068TH.
2
Inspiratory capacity and forced expiratory volume in the first second in exacerbation of chronic obstructive pulmonary disease.
Clin Respir J. 2008 Jan;2(1):36-40. doi: 10.1111/j.1752-699X.2007.00040.x.
3
Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease.
Am J Respir Crit Care Med. 2017 Feb 1;195(3):324-330. doi: 10.1164/rccm.201605-1014OC.
4
'Exacerbation-free time' to assess the impact of exacerbations in patients with chronic obstructive pulmonary disease (COPD): a prospective observational study.
NPJ Prim Care Respir Med. 2018 Apr 3;28(1):12. doi: 10.1038/s41533-018-0079-5.
5
Exacerbations and lung function decline in COPD: new insights in current and ex-smokers.
Respir Med. 2007 Jun;101(6):1305-12. doi: 10.1016/j.rmed.2006.10.012. Epub 2006 Nov 16.
6
Chronic obstructive pulmonary disease phenotypes: the future of COPD.
Am J Respir Crit Care Med. 2010 Sep 1;182(5):598-604. doi: 10.1164/rccm.200912-1843CC. Epub 2010 Jun 3.
7
Combined Forced Expiratory Volume in 1 Second and Forced Vital Capacity Bronchodilator Response, Exacerbations, and Mortality in Chronic Obstructive Pulmonary Disease.
Ann Am Thorac Soc. 2019 Jul;16(7):826-835. doi: 10.1513/AnnalsATS.201809-601OC.
8
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.
Thorax. 2002 Oct;57(10):847-52. doi: 10.1136/thorax.57.10.847.
9
Clinical features of Japanese patients with exacerbations of chronic obstructive pulmonary disease.
BMC Pulm Med. 2020 Dec 7;20(1):318. doi: 10.1186/s12890-020-01362-w.
10
[Chronic obstructive pulmonary disease exacerbations and their impact on the long-term natural history of the disease].
Presse Med. 2008 Nov;37(11):1599-603. doi: 10.1016/j.lpm.2008.08.004. Epub 2008 Sep 26.
引用本文的文献
1
Analysis of the Comorbid Course of Chronic Obstructive Pulmonary Disease.
J Pers Med. 2023 Jul 24;13(7):1179. doi: 10.3390/jpm13071179.
2
Increased mortality associated with frequent exacerbations in COPD patients with mild-to-moderate lung function impairment, and smokers with normal spirometry.
Respir Med X. 2021 Nov;3. doi: 10.1016/j.yrmex.2020.100025. Epub 2020 Dec 29.
3
Correlation between Telomere Length and Chronic Obstructive Pulmonary Disease-Related Phenotypes: Results from the Chronic Obstructive Pulmonary Disease in Dusty Areas (CODA) Cohort.
Tuberc Respir Dis (Seoul). 2021 Jul;84(3):188-199. doi: 10.4046/trd.2021.0015. Epub 2021 May 13.
4
Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations.
Clin Chest Med. 2020 Sep;41(3):421-438. doi: 10.1016/j.ccm.2020.06.007.
5
Evaluating Mobile Apps and Biosensing Devices to Monitor Physical Activity and Respiratory Function in Smokers With and Without Respiratory Symptoms or Chronic Obstructive Pulmonary Disease: Protocol for a Proof-of-Concept, Open-Label, Feasibility Study.
JMIR Res Protoc. 2020 Mar 26;9(3):e16461. doi: 10.2196/16461.
6
Relationship of Blood Eosinophils with Fractional Exhaled Nitric Oxide and Pulmonary Function Parameters in Chronic Obstructive Pulmonary Disease (COPD) Exacerbation.
Med Sci Monit. 2020 Mar 12;26:e921182. doi: 10.12659/MSM.921182.
7
Identification of Chronic Obstructive Pulmonary Disease Axes That Predict All-Cause Mortality: The COPDGene Study.
Am J Epidemiol. 2018 Oct 1;187(10):2109-2116. doi: 10.1093/aje/kwy087.
8
Do frequent moderate exacerbations contribute to progression of chronic obstructive pulmonary disease in patients who are ex-smokers?
Int J Chron Obstruct Pulmon Dis. 2015 Mar 10;10:525-33. doi: 10.2147/COPD.S76475. eCollection 2015.
9
Using cluster analysis to identify phenotypes and validation of mortality in men with COPD.
Lung. 2014 Dec;192(6):889-96. doi: 10.1007/s00408-014-9646-x. Epub 2014 Oct 7.
10
Analyzing networks of phenotypes in complex diseases: methodology and applications in COPD.
BMC Syst Biol. 2014 Jun 25;8:78. doi: 10.1186/1752-0509-8-78.
本文引用的文献
1
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
N Engl J Med. 2007 Feb 22;356(8):775-89. doi: 10.1056/NEJMoa063070.
2
A single nucleotide polymorphism in the CCL1 gene predicts acute exacerbations in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med. 2006 Oct 15;174(8):875-85. doi: 10.1164/rccm.200603-443OC. Epub 2006 Jul 24.
3
Genetic association analysis of functional impairment in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med. 2006 May 1;173(9):977-84. doi: 10.1164/rccm.200509-1452OC. Epub 2006 Feb 2.
4
COPD exacerbations .1: Epidemiology.
Thorax. 2006 Feb;61(2):164-8. doi: 10.1136/thx.2005.041806.
5
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.
Thorax. 2005 Nov;60(11):925-31. doi: 10.1136/thx.2005.040527. Epub 2005 Jul 29.
6
Impact of preventing exacerbations on deterioration of health status in COPD.
Eur Respir J. 2004 May;23(5):698-702. doi: 10.1183/09031936.04.00121404.
7
The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.
N Engl J Med. 2004 Mar 4;350(10):1005-12. doi: 10.1056/NEJMoa021322.
8
Withdrawal from treatment as an outcome in the ISOLDE study of COPD.
Chest. 2003 Oct;124(4):1350-6. doi: 10.1378/chest.124.4.1350.
9
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.
Thorax. 2002 Oct;57(10):847-52. doi: 10.1136/thorax.57.10.847.
10
Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study.
Am J Respir Crit Care Med. 2001 Aug 1;164(3):358-64. doi: 10.1164/ajrccm.164.3.2010017.
Zotero 插件